KRYS
Krystal Biotech, Inc.
KRYS has the edge over OSCR overall, supported by lower modeled downside and stronger modeled upside.
OSCR
Oscar Health, Inc.
OSCR's outlook is improving, though it still trails on the overall score.
KRYS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
KRYS's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
KRYS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 35x | $261 | -15% |
| Forward | 35x | $306 | — |
| Current | 42x | $306 | — |
| Fair | 44x | $321 | +5.1% |
| Expensive | 79x | $579 | +89% |
Historical ranges are pointers, not guarantees.
KRYS's PE is in its fair range at 42x. If earnings grow as analysts expect, today's price would be 35x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over KRYS in the historical PE scenario, which offers more potential upside but is not a forecast.
KRYS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for KRYS, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
KRYS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.68 | +18% |
| Q3 2026 | $7.36 | +10% |
| Q2 2026 | $7.97 | +62% |
| Q1 2026 | $7.47 | +79% |
| Q4 2025 | $6.84 | +128% |
| Q3 2025 | $6.68 | +221% |
| Q2 2025 | $4.93 | +24% |
| Q1 2025 | $4.17 | +91% |
| Q4 2024 | $3.00 | +669% |
KRYS has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
KRYS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $127.3M | +30% |
| Q2 2026 | $119.2M | +24% |
| Q1 2026 | $116.4M | +32% |
| Q4 2025 | $107.1M | +18% |
| Q3 2025 | $97.8M | +17% |
| Q2 2025 | $96M | +37% |
| Q1 2025 | $88.2M | +95% |
| Q4 2024 | $91.1M | +116% |
KRYS's revenue has grown year over year every quarter since late 2024: $127M last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 56% | +14 points |
| Q2 2026 | 49% | +8.1 points |
| Q1 2026 | 46% | +5.1 points |
| Q4 2025 | 41% | -4.1 points |
| Q3 2025 | 42% | +16 points |
| Q2 2025 | 41% | +29 points |
| Q1 2025 | 41% | +56 points |
| Q4 2024 | 45% | +38 points |
KRYS has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over KRYS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
KRYS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $90.3M | +138% |
| Q2 2026 | $71.2M | +40% |
| Q1 2026 | $73.2M | +196% |
| Q4 2025 | $75.4M | +45% |
| Q3 2025 | $38M | -34% |
| Q2 2025 | $50.8M | +$56.1M |
| Q1 2025 | $24.8M | +69% |
| Q4 2024 | $52M | +$61.1M |
KRYS has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
KRYS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +181K shares |
| 1 year | +3.4% | +1M shares |
| 3 years | +6.7% | +1.9M shares |
| 5 years | +39% | +8.6M shares |
| Available history | +94% | +14.9M shares |
KRYS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
KRYS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.0x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.7x | Net Cash |
| Q4 2025 | -3.0x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -2.5x | Net Cash |
| Q1 2025 | -2.7x | Net Cash |
| Q4 2024 | -4.8x | Net Cash |
KRYS has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over KRYS on leverage, with a lower net debt burden relative to earnings.
KRYS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.9 | Neutral |
| Stochastic | 31.3 | Neutral |
KRYS's weekly RSI is 46 (neutral) and its Stochastic is 31 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
KRYS PE vs Healthcare Sector
| Metric | KRYS | Sector median | Relative |
|---|---|---|---|
| PE | 42x | 26x | 61% above |
| PE % | 42 | 29 | 13 pts above |
KRYS is trading at 42x earnings, a 61% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over KRYS on valuation relative to its sector.
KRYS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $320.8 | 4.7% below |
| 20 week MA | $336.9 | 9.3% below |
| 50 week MA | $300.8 | 1.6% above |
| 100 week MA | $231.7 | 32% above |
| 200 week MA | $184.5 | 66% above |
KRYS has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 66% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over KRYS on trend strength, trading above more of its moving averages.
KRYS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $60.2 | $60.6 | +0.7% |
| 2021 | $60.6 | $72.3 | +19% |
| 2022 | $72.3 | $76.6 | +5.9% |
| 2023 | $76.6 | $124.1 | +62% |
| 2024 | $124.1 | $159.3 | +28% |
| 2025 | $159.3 | $252.2 | +58% |
| 2026 YTD | $252.2 | $305.7 | +21% |
KRYS has finished every year since 2020 higher, and it's up 21% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over KRYS on returns for 2026, with the stronger performance.